Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Gains from Investment Securities: 2019-2024

Historic Gains from Investment Securities for Foghorn Therapeutics (FHTX) over the last 4 years, with Dec 2024 value amounting to $860,000.

  • Foghorn Therapeutics' Gains from Investment Securities fell 101.13% to -$8,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $1.3 million, marking a year-over-year decrease of 50.06%. This contributed to the annual value of $860,000 for FY2024, which is 75.78% down from last year.
  • As of FY2024, Foghorn Therapeutics' Gains from Investment Securities stood at $860,000, which was down 75.78% from $3.6 million recorded in FY2023.
  • Foghorn Therapeutics' Gains from Investment Securities' 5-year high stood at $3.6 million during FY2023, with a 5-year trough of $69,000 in FY2020.
  • For the 2-year period, Foghorn Therapeutics' Gains from Investment Securities averaged around $2.2 million, with its median value being $2.2 million (2023).
  • As far as peak fluctuations go, Foghorn Therapeutics' Gains from Investment Securities surged by 7,000.00% in 2020, and later crashed by 75.78% in 2024.
  • Over the past 3 years, Foghorn Therapeutics' Gains from Investment Securities (Yearly) stood at $69,000 in 2020, then reached $3.6 million in 2023, then plummeted by 75.78% to $860,000 in 2024.